Pangaea Data and AstraZeneca have forged a multi-year partnership focused on advancing precision healthcare with multimodal AI.
Multimodal AI refers to a form of the technology that processes and interprets information originated from multiple data sources such as text, images, and video.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
The companies will use the technology to make AI-driven clinical decision-making available at scale, improving how patients are identified, diagnosed, treated and connected to existing therapies and clinical trials.
Pangaea is experienced in deploying AI and patient-intelligence platforms. The company’s clinical systems are currently used to close care gaps and optimise patient outcomes across areas including chronic kidney disease (CKD), chronic obstructive pulmonary disease (COPD), metastatic breast cancer and gastric cancer.
In combination with AstraZeneca’s scientific expertise, the companies have said their strategic partnership will advance multimodal AI models and applications to support clinical trials and point‑of‑care treatment decisions.
Pangaea’s founder and CEO Vibhor Gupta commented: “We are excited to collaborate with AstraZeneca on this mission to transform care by ensuring that patients are connected to life‑changing therapies and trials effectively in a compliant and financially sustainable manner.”
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataKey to the partnership is AstraZeneca’s role in sponsoring the configuration, validation, and deployment of Pangaea’s enterprise‑grade platform that combines clinical, imaging, genomic, pathology and real‑world data.
Access to generative and predictive AI tools developed by Microsoft and NVIDIA will play an additional role in helping to meet the overall aims of Pangaea and AstraZeneca’s collaboration.
Pangea said its platform that applies clinical-grade AI to discover untreated, misdiagnosed, and under-treated patients at scale will be further strengthened by its participation in the NVIDIA Inception and Microsoft Pegasus programmes. The tech giants’ programmes are initiatives that support startups with their existing tech offerings while also assisting in their commercialisation activities.
Microsoft’s role in the Pangea-AstraZeneca partnership will involve connecting Pangaea’s systems into existing clinical workflows where it will use ambient listening and agentic AI orchestration to enable real-time, context-aware recommendations at the point of care.
Further computing and infrastructure technology from Microsoft, such as its Azure AI super‑computing clusters and Nvidia’s GPUs and Azure OpenAI Service, will provide the processing capacity to train, deploy and refine multimodal models quickly and securely, the companies added.
David Dellamonica, global head of digital care pathway optimisation at AstraZeneca, said: “By combining our scientific leadership with Nvidia and Microsoft’s AI capabilities, and enabling real‑world reach through Pangaea Data, we believe this technology will support our aim to transform outcomes for millions of patients.”
The collaboration follows a partnership between AstraZeneca’s rare disease business, Alexion, with Pangaea Data announced in June 2025. The aim of the partnership was to fund the startup’s development of an AI tool for detecting hypophosphatasia (HPP).
